Suppr超能文献

通过感染野生型或变异病毒的K18-hACE2小鼠血清鉴定的新冠病毒刺突蛋白的免疫显性线性B细胞表位

Immunodominant Linear B-Cell Epitopes of SARS-CoV-2 Spike, Identified by Sera from K18-hACE2 Mice Infected with the WT or Variant Viruses.

作者信息

Levy Yinon, Alcalay Ron, Zvi Anat, Makdasi Efi, Peretz Eldar, Noy-Porat Tal, Chitlaru Theodor, Mandelboim Michal, Mazor Ohad, Rosenfeld Ronit

机构信息

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 7410001, Israel.

The Central Virology Laboratory, Israel Ministry of Health, Tel Hashomer, Ramat Gan 5266202, Israel.

出版信息

Vaccines (Basel). 2022 Feb 7;10(2):251. doi: 10.3390/vaccines10020251.

Abstract

SARS-CoV-2 surface spike protein mediates the viral entry into the host cell and represents the primary immunological target of COVID-19 vaccines as well as post-exposure immunotherapy. Establishment of the highly immunogenic B-cell epitope profile of SARS-CoV-2 proteins in general, and that of the spike protein in particular, may contribute to the development of sensitive diagnostic tools and identification of vaccine` candidate targets. In the current study, the anti-viral antibody response in transgenic K18-hACE-2 mice was examined by implementing an immunodominant epitope mapping approach of the SARS-CoV-2 spike. Serum samples for probing an epitope array covering the entire spike protein were collected from mice following infection with the original SARS-CoV-2 strain as well as the B.1.1.7 Alpha and B.1.351 Beta genetic variants of concern. The analysis resulted in distinction of six linear epitopes common to the humoral response against all virus variants inspected at a frequency of more than 20% of the serum samples. Finally, the universality of the response was probed by cross-protective in vitro experiments using plaque-reducing neutralization tests. The data presented here has important implications for prediction of the efficacy of immune countermeasures against emerging SARS-CoV-2 variants.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)表面刺突蛋白介导病毒进入宿主细胞,是2019冠状病毒病(COVID-19)疫苗以及暴露后免疫治疗的主要免疫靶点。确定SARS-CoV-2蛋白,尤其是刺突蛋白的高免疫原性B细胞表位谱,可能有助于开发灵敏的诊断工具并识别疫苗候选靶点。在本研究中,通过对SARS-CoV-2刺突蛋白实施免疫显性表位定位方法,检测了转基因K18-hACE-2小鼠的抗病毒抗体反应。在用原始SARS-CoV-2毒株以及值得关注的B.1.1.7 Alpha和B.1.351 Beta基因变体感染小鼠后,收集用于探测覆盖整个刺突蛋白的表位阵列的血清样本。分析结果区分出了六种线性表位,这些表位在针对所有检测病毒变体的体液反应中常见,在血清样本中的出现频率超过20%。最后,通过使用蚀斑减少中和试验的交叉保护性体外实验探究了反应的普遍性。本文提供的数据对于预测针对新出现的SARS-CoV-2变体的免疫对策的效果具有重要意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验